Hi {{Recipient.FirstName}}, Welcome to this week’s edition of the Wholesale Investor newsletter. Keep up to date with the latest news within our Australian and APAC ecosystem, and discover unique and relevant opportunities that fit your investment portfolio.
We are just over a week away from Venture & Capital 2022 investment conference happening LIVE in Sydney on 25th to 27th July. Featuring 52 speakers including prominent names from Binance, Coca Cola Ventures, and Tractor Ventures, this 3-day event will showcase 90+ presenting companies and discuss insights on venture capital and angel investing delivered by Australia’s top VCs. Last week, we’ve hosted V&C London and it was a huge success! Don’t miss out on the next V&C in Sydney. Register here. Enjoy this week’s content. |
|
|
| Multi-Awarded LegalTech Firm Tops in Financial Times APAC High Growth Companies List, AFR Fast Starters, and Deloitte’s APAC Technology Fast 500
SECTORS: Technology, Business Solutions, e-Commerce STAGE: Bridging Round
Sprintlaw turns legal services into a suite of simple, standardised package and subscription products which cover the majority of legal needs for small businesses. The company has provided legal assistance to 30,000+ startups and small businesses in Australia and the UK. Sprintlaw is APAC's fastest growing legal firm, and was the top-ranked legal business in the Financial Times APAC High Growth Companies List (2022), the AFR Fast Starters (2021), and the Deloitte’s APAC Technology Fast 500 (2021).
The firm has won many industry awards, including NewLaw Firm of the Year (2020, 2021) and Innovator of the Year (2019) at the Australian Law Awards, Australasian Lawyer’s Employer of Choice Award (2020, 2021), and the LexisNexis Legal Innovation Index Award (2018). |
|
|
| ASX-Listed Pharmaceutical’s Anti-Infective Recognized by Pew Charitable Trusts
SECTORS: Biotechnology, Life Sciences, Pharmaceuticals STAGE: Seed Round
Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) is developing new classes of synthetic anti-infectives designed to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens. Recce’s anti-infective pipeline includes three patented, broad-spectrum, and synthetic polymer anti-infectives – one of which is RECCE® 327.
The FDA has awarded RECCE® 327 Qualified Infectious Disease Product designation, labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval. RECCE® 327 has also been included on The Pew Charitable Trusts Global New Antibiotics in Development Pipeline as the world’s only synthetic polymer and sepsis drug candidate in development. |
|
|
Fintech with A$1M Annual Revenue Adds Award-winning Fintech Product Specialist |
Selfmade is a digital tax agent and financial services platform that provides both individuals and SMSFs with a range of high-tech professional services including tax lodgements, compliance, and administration. The company has added Ben Styles to the team developing its new personal tax product which is launching this financial year. Ben has worked as Executive General Manager of Product – Financial Services at Xero.
|
|
|
Natural Health Product Manufacturer with 22,000+ Terpene Products Sold |
Primal Organix is a natural health product manufacturer whose botanical terpene supplement drops interact with the human endocannabinoid system, enabling people to manage various health conditions and promote wellbeing. It has generated A$792K in sales revenue, has sold 22,000+ products, and sells to 120+ outlets.
|
|
|
24/7 Digital Exchange Platform Offering Digital Gold, Silver, Platinum, and Palladium Tokens |
Metex Exchange is an AUSTRAC-registered digital exchange for metals and cryptocurrency trading 24/7/365. Metex is the only digital exchange delivering four precious metals globally to the retail market. Metex has hit a key milestone: It now offers AUD deposits via PayID, EFT and credit card. |
|
|
Click on the link to read the full article for each company and register your interest if you wish to know more about their investment opportunity. |
|
|
Clinical study validates targeting LSD1 inhibition for metastatic breast cancer | Results published in leading cancer journal Frontiers of Oncology |
EpiAxis Therapeutics has published the results of its EPI-PRIMED clinical trial in a leading journal. The trial used an epigenetic inhibitor in combination with chemotherapy to treat metastatic cancer. The results demonstrate that nuclear inhibition of LSD1 is possible and results in the reprogramming of cancer cells. The results provide proof of concept for EpiAxis' current drug development program for its therapies to inhibit nuclear LSD1.
|
|
|
Education company achieves gross sales over 120% since launching new business model | Generated more than $1.6M in revenue in 2022 |
Learning Pod Group has announced significant sales growth since it introduced a new business model, a new indoor play centre model. Learning Pod Group has grown sales by 120% since it introduced a new business model, a new indoor play centre model. In 2022 alone, Learning Pod has generated more than $1.6M in revenue.
|
|
|
B2B DeepTech/FinTech extends its proposition from Financial Services to Machine Learning |
MatLogica’s technology unlocks the full potential of modern CPUs for computationally intensive tasks. MatLogica has been recognised as a 'Category Leader’ in the ‘Chartis RiskTech Quadrant® for xVA Solutions: Analytical Components'. MatLogica has just reached a milestone, expanding into machine learning.
|
|
|
| Solvv | Kelly Max
Web 3.0 | NFT | Digital Media |
Solvv democratizes podcasting, fast-tracks content creation, and facilitates bite-sized content consumption. Available on iOS, Android, and the web, the platform combines short-form audio, social networking, and Web3-based engagement models. CEO Kelly Max walks us through the technological innovations in Web 3. Watch the interview to get insights into this space. |
|
|
Class Order:
(A) the information contained in the Publication about the proposed business opportunity and the securities or scheme interests is not intended to be the only information on which the investment decision is made and is not a substitute for a disclosure document, Product Disclosure Statement or any other notice that may be required under the Act,as that Act may apply to the investment. Detailed information may be needed to make an investment decision, for example: financial statements; a business plan; information about ownership of intellectual or industrial property; or expert opinions including valuations or auditors’ reports; and (B) a prospective investor is strongly advised to take appropriate professional advice before accepting an offer for issue or sale of any securities or scheme interests.
|
Wholesale Investor Level 9, 100 William St Woolloomooloo NSW 2011
1300 597 595 |
|
|
|